X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Lilly expands its portfolio in cardiometabolic diseases with Versanis' lead asset is BYM-338 (bimagrumab), a first-in-class, fully human monoclonal antibody, being assessed in combination with semaglutide in adults living with overweight or obesity.
Lead Product(s): Bimagrumab,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: BYM-338
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,925.0 million Upfront Cash: $1,925.0 million
Deal Type: Acquisition August 14, 2023
Details:
Through the acquisition, Lilly will expands its portfolio in cardiometabolic diseases by gaining Versanis' lead asset is bimagrumab, a first-in-class, fully human monoclonal antibody, being assessed in combination with semaglutide in adults living with overweight or obesity.
Lead Product(s): Bimagrumab,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: BYM-338
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,925.0 million Upfront Cash: $1,925.0 million
Deal Type: Acquisition July 14, 2023
Details:
BYM338 (bimagrumab) is a fully human IgG1/lamda mAb with picomolar affinity for both activin type II receptors A and B that blocks binding of ligands, including myostatin and activins. It decreases body fat at the same time increases muscle mass.
Lead Product(s): Bimagrumab,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: BYM338
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
BYM338 (bimagrumab) is a first-in-class, fully human IgG1/λ monoclonal antibody to activin type II receptors that blocks binding of ligands including myostatin, activins and GDF11.
Lead Product(s): Bimagrumab,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: BYM338
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
BYM338 (bimagrumab) is a first-in-class, fully human IgG1/λ monoclonal antibody to activin type II receptors that blocks binding of ligands including myostatin, activins and GDF11.
Lead Product(s): Bimagrumab
Therapeutic Area: Nutrition and Weight Loss Product Name: BYM338
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
BYM338 (Bimagrumab) is a first-in-class activin type II receptor monoclonal antibody previously evaluated in various muscle wasting indications based on its effects on muscle anabolism.
Lead Product(s): Bimagrumab
Therapeutic Area: Endocrinology Product Name: BYM338
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
